Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)

China · Delayed Price · Currency is CNY

5.64

-0.02 (-0.35%)

Aug 12, 2026, 11:29 AM CST

-33.10% (1Y)

Market Cap	5.75B -32.9%
Revenue (ttm)	3.68B -7.4%
Net Income	168.94M -28.2%
EPS	0.16 -30.4%
Shares Out	1.02B
PE Ratio	35.36
Forward PE	23.58
Dividend	0.06 (1.00%)
Ex-Dividend Date	Jul 15, 2026

Volume	4,926,500
Open	5.66
Previous Close	5.66
Day's Range	5.60 - 5.72
52-Week Range	4.89 - 8.73
Beta	0.78
Analysts	Strong Buy
Price Target	8.17 (+44.86%)
Earnings Date	Aug 26, 2026

About SHA:600223

Lushang Freda Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of cosmetics, pharmaceuticals, raw materials, and additives in China. It is involved in property management services. The company provides facial cleansers, lotions, creams, sprays, masks, and other products. It also offers products in the field of dermatology, orthopedics, ophthalmology, gynecology, and pediatrics, respiratory, endocrinology, andrology, tonic, and plasters, as well as hyaluronic acid and its derivatives, bio-fermentation, plant ex... [Read more]

Industry Real Estate - Development

Sector Real Estate

Founded 1993

Employees 3,514

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600223

Full Company Profile

Financial Performance

In 2025, SHA:600223's revenue was 3.65 billion, a decrease of -8.33% compared to the previous year's 3.98 billion. Earnings were 187.75 million, a decrease of -22.90%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 600223 stock is "Strong Buy." The 12-month stock price target is ¥8.17, which is an increase of 44.86% from the latest price.

Price Target

¥8.17

(44.86% upside)

Analyst Consensus: Strong Buy

Stock Forecasts